Group 1 - Novo Nordisk, a leader in diabetes and weight loss drugs, has underperformed the S&P 500 index since March 30, 2025 [1] - The author has a long position in Novo Nordisk shares, indicating a belief in the company's potential [1] Group 2 - The article reflects a broader investment strategy that includes a focus on technology companies and opportunities in crypto, while also considering global markets [1]